Literature DB >> 10627859

Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.

K Bjøro1, K Skaug, T Haaland, S S Frøland.   

Abstract

The clinical course of HCV infection in patients with primary hypogammaglobulinaemia appears to be more severe than in immunocompetent patients. We studied the long-term course of chronic HCV infection in 20 Norwegian hypogammaglobulinaemia patients with a 13-15 year known history of HCV infection. Twelve of 20 patients developed cirrhosis during the observation period (1984-1999), and the remaining eight also had chronic liver disease verified by liver biopsy in the majority of the cases. Eleven of the 20 patients are dead. Two died following liver transplantation for HCV cirrhosis. Five died due to terminal liver failure without receiving a liver allograft. Two patients died from other causes, but with advanced liver disease contributing to the outcome, while two deaths were unrelated to the HCV infection. Among patients with common variable immunodeficiency (CVI), five out of six are dead. Two patients cleared the hepatitis C virus 3 years following interferon monotherapy, while three patients achieved a sustained response to combination therapy with interferon and ribavirin. Viral load did not seem to have a major impact on disease progression. Our results emphasize the severity of hepatitis C virus infection in patients with hypogammaglobulinaemia. Patients with CVI appear to have the poorest prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10627859     DOI: 10.1093/qjmed/92.8.433

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  15 in total

Review 1.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

Authors:  Ype P de Jong; Marcus Dorner; Michiel C Mommersteeg; Jing W Xiao; Alejandro B Balazs; Justin B Robbins; Benjamin Y Winer; Sherif Gerges; Kevin Vega; Rachael N Labitt; Bridget M Donovan; Erick Giang; Anuradha Krishnan; Luis Chiriboga; Michael R Charlton; Dennis R Burton; David Baltimore; Mansun Law; Charles M Rice; Alexander Ploss
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

Review 3.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

4.  Hepatitis C infection and chronic renal diseases.

Authors:  Aline Gonzalez Vigani
Journal:  Hepatol Int       Date:  2012-03-15       Impact factor: 6.047

5.  Sustained virologic response following HCV eradication in two brothers with X-linked agammaglobulinaemia.

Authors:  Diarmaid D Houlihan; Eoin R Storan; John M Lee
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

Review 6.  Common variable immunodeficiency and the gastrointestinal tract.

Authors:  Ishaan Kalha; Joseph H Sellin
Journal:  Curr Gastroenterol Rep       Date:  2004-10

7.  Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.

Authors:  Nicola Strnad-Trojan; Richard Linde; Janine Reichenbach; Jörg Trojan; Stefan Zeuzem; Stefan Zielen
Journal:  Eur J Pediatr       Date:  2006-02-04       Impact factor: 3.183

8.  Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection.

Authors:  Daniel S Fierer; Douglas T Dieterich; M Isabel Fiel; Andrea D Branch; Kristen M Marks; Dahlene N Fusco; Ricky Hsu; Davey M Smith; Joshua Fierer
Journal:  Clin Infect Dis       Date:  2012-12-21       Impact factor: 9.079

9.  Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver.

Authors:  Søren U Nielsen; Margaret F Bassendine; Alastair D Burt; Debra J Bevitt; Geoffrey L Toms
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

10.  Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.

Authors:  Rachael E Swann; Vanessa M Cowton; Mark W Robinson; Sarah J Cole; Stephen T Barclay; Peter R Mills; Emma C Thomson; John McLauchlan; Arvind H Patel
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.